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Abstract
Background and Purpose: Antioxidant enzymes like cop-
per/zinc superoxide dismutase (SOD), catalase and glu-
thatione peroxidase (GSHPx) are part of intracellular pro-
tection mechanisms to overcome oxidative stress and
are known to be activated in vascular diseases and acute
stroke. We investigated the differences of antioxidant
capacity in acute stroke and stroke risk patients to eluci-
date whether the differences are a result of chronic low
availability in arteriosclerosis and stroke risk or due to
changes during acute infarction. Methods: Antioxidant
enzymes were examined in 11 patients within the first
hours and days after acute ischemic stroke and com-
pared to risk- and age-matched patients with a history of
stroke in the past 12 months (n = 17). Antioxidant profile
was determined by measurement of glutathione (GSH),
malondialdehyde (MDA), SOD, GSHPx and minerals
known to be involved in antioxidant enzyme activation
like selenium, iron, copper and zinc. Results: In compari-
son to stroke risk patients, patients with acute ischemic
stroke had significant changes of the GSH system during
the first hours and days after the event: GSH was signifi-
cantly elevated in the first hours (p ! 0.01) and GSHPx
was elevated 1 day after the acute stroke (p ! 0.05). Sele-
nium, a cofactor of GSHPx, was decreased (p ! 0.01).
GSHPx levels were negatively correlated with National
Institutes of Health Stroke Scale (NIHSS) scores on ad-
mission (r = –0.84, p ! 0.001) and NIHSS scores after 7
days (r = –0.63, p ! 0.05). MDA levels showed a trend for
elevation in the first 6 h after the acute stroke (p = 0.07).
No significant differences of SOD, iron, copper nor zinc
levels could be identified. Conclusions: Differences of
antioxidant capacity were found for the GSH system with
elevation of GSH and GSHPx after acute stroke, but not
for other markers. The findings support the hypothesis
that changes of antioxidant capacity are part of acute
adaptive mechanisms during acute stroke.
Copyright © 2004 S. Karger AG, Basel
Free radicals and reactive oxygen species (ROS) are
believed to cause biological cell damage. A sensitive bal-
ance between generation and neutralization of oxidants
by different intra- and extracellular defense mechanisms
helps to protect vital cell components. Circulating scav-
enging antioxidants with a high redox potential like ascor-
bic acid, tocopherols, ß-carotene and ubiquinone, intrin-
sic antioxidants like bilirubin, urate and albumin as well
as intracellular antioxidant enzymes like gluthatione per-
oxidase (GSHPx), superoxide dismutase (SOD) and cata-
lase maintain this equilibrium.
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Arteriosclerotic vascular damage is believed to be one of
the consequences of increased oxidative stress including
excessive generation of ROS, oxidation of lipoproteins and
formation of arteriosclerotic plaques. Oxidative stress is
also one of the mechanisms involved in neuronal damage
induced by ischemia/reperfusion [1, 2]. The antioxidant
activity of plasma may be an important factor providing
protection from neurological damage caused by stroke-
associated oxidative stress [3, 4]. Acute ischemia leads to
increased production of free radicals and ROS in tissue
and plasma [1]. During the early phase of ischemia and
reperfusion, antioxidants can be mobilized, though antiox-
idant capacity might be limited by chronically low avail-
ability, consumption of neutralizing scavenging antioxi-
dants or excessive oxidative stress [3, 5]. This study was
designed to examine the differences and changes of antiox-
idant enzymes in acute stroke to elucidate whether there
are acute adaptive changes to overcome oxidative stress.
Subjects and Methods
Patient Selection
Antioxidant markers were examined in two groups of patients:
(a) in patients within the first hours and days after acute stroke
(group A, n = 11) and (b) in age- and risk-matched patients with a
history of stroke in the past 12 months (group B, n = 17). Group A
consisted of 11 patients with symptoms of acute stroke admitted
within 6 h after onset of neurologic deficit to the emergency room of
Krankenhaus Munich-Harlaching. Blood was taken within 6 h after
onset of symptoms and cranial CT scan was performed to exclude
intracranial hemorrhage and to determine the size of infarction.
Patients also had blood controls 1, 3 and 7 days after acute stroke.
Neurologic examination was recorded by the National Institutes of
Health Stroke Scale (NIHSS) [6] on admission and day 7 and a
numeric risk score was calculated according to the Copenhagen City
Heart Study (CCHS) risk score for stroke risk patients [7]. Type and
etiology of infarction were determined by examination results of cra-
nial CT, duplex ultrasonography, ECG, echocardiography and clini-
cal situation.
Group B consisted of 17 age- and risk-matched patients with sim-
ilar cardiovascular risk factors having suffered from minor stroke in
the past 12 months and presenting at the outpatient clinic for check-
up visits. None of the patients was suffering from another inflamma-
tory, degenerative or malignant disease. All patients gave their writ-
ten informed consent. They underwent neurological examination,
cardiovascular risk factors were checked by patient history and clini-
cal parameters, and CCHS risk score was calculated.
Analysis of Blood Samples
Venous blood samples were taken, serum and whole EDTA blood
was frozen immediately and stored at –70°C for a maximum of 6
months until determination of antioxidant enzymes (GSHPx, SOD),
markers of peroxidation [malondialdehyde (MDA), glutathione
(GSH)] and minerals (selenium, copper, zinc, iron) involved in the
regulation of antioxidant enzymes.
Serum GSHPx was determined by the method described by
Paglia and Valentine [8] coupling the peroxidase reaction with the
reduction of oxidized GSH reductase and NADPH. Whole blood
SOD activity was measured from lysate by a chemiluminometric
method using the RanSOD 125 kit (Randox Laboratories, UK ) and
serum MDA was determined by condensation with thiobarbituric
acid and photometric determination of the pink chromogen [9].
Whole blood GSH was measured by fluometric reaction with Ell-
manns reagent described by Mergel et al. [10]. For determination of
minerals, flame and flameless atomic absorption spectroscopy was
used.
Normal values were based on laboratory reference values includ-
ing 101 healthy subjects analyzed under the same conditions (20
female, 81 male). Normal values were 1.6–2.4 Ìmol/l for MDA, 68–
97 Ìmol/l for GSH, 96–150 U/l for GSHPx, 15–22 U/Ìmol hemoglo-
bin for SOD, 0.72–1.33 Ìmol/l for selenium in serum, 9–26 Ìmol/l
for copper, 62–102 Ìmol/l for zinc and 51.7–95.7 Ìmol/l for iron in
whole blood [11].
Results are expressed as means B SD. For statistical analysis, the
Mann-Whitney U test and Spearman rank correlation coefficient
were used. A value of p ! 0.05 was considered significant.
Results
A description of the patients and their risk profile is
presented in table 1. In patients with acute stroke, MDA
levels showed a trend for elevation in the first 6 h after
stroke (2.1 B 0.6 Ìmol/l, p = 0.07), which decreased to 1.7
B 0.2 Ìmol/l after 7 days similar to the levels of stroke
risk patients (1.7 B 0.5 Ìmol/l, table 2). In more than half
of the patients of group B, GSH levels were below the nor-
mal range. Compared to them, patients with acute stroke
showed significantly elevated GSH levels on admission
(p ! 0.01, table 2).
Levels of GSHPx were elevated during the first days
after acute stroke as well, showing significant elevation 1
day after the acute event (table 2, p ! 0.05). GSHPx levels
during the first 6 h after acute stroke were negatively cor-
related with the NIHSS score on admission (r = –0.84, p !
0.001) and the NIHSS score after 7 days (r = –0.63, p !
0.05, fig. 1).
Selenium in serum, known to be a cofactor for GSHPx,
was significantly lower in acute stroke compared to stroke
risk patients (p ! 0.05, table 2).
Whole blood SOD activity was similar in both groups
of patients (table 2). There were no differences of copper
or zinc – cofactors of SOD – between the groups (copper:
13.7 B 1.4 Ìmol/l versus 14.0 B 1.7 Ìmol/l; zinc: 90 B 11
versus 89 B 12 Ìmol/l). No difference in whole blood iron
was found.
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Table 1. Patient data and risk profile
Patients with acute stroke Patients with history of stroke
Patients 11 17
Female/male 6/5 3/14
Age, years 62.2B8.4 63.4B7.8
Systolic blood pressure, mm Hg 153B12 143B20 
Diastolic blood pressure, mm Hg 87B7 81B10 
CCHS stroke risk score1 15.7B9.4 (8–38) 16.1B7.9 (3–30)
NIHSS score on admission 7.6B6.6 (0–20)
NIHSS score on day 7 3.9B5.3 (0–18)
Type of ischemia PRIND/TIA: 7 pat. (64)
stroke: 4 pat. (36)
PRIND/TIA: 11 pat. (65)
stroke: 6 pat. (35)
Size of infarction 4 pat.: small lesion2 (36)
3 pat.: moderate lesion3 (27)
4 pat.: large lesion4 (36)
not available
Type of infarction 4 atherothrombotic (36)
3 cardioembolic (27)
4 microangiopathic (36)
9 atherothrombotic (53)
4 cardioembolic (24)
4 microangiopathic (24)
Stroke prevention 5 pat.: ASS (45)
2 pat.: clopidogrel (18)
4 pat.: anticoagulation (36)
7 pat.: ASS (41)
5 pat.: clopidogrel (29)
5 pat.: anticoagulation (29)
PRIND = Prolonged ischemic neurological deficit; TIA = transient ischemic attack; pat. = patients. Figures in
parentheses indicate ranges or percentages.
1 CCHS prospective stroke risk score: a risk evaluation by age, blood pressure, atrial fibrillation, smoking, left
ventricular hypertrophy, treatment of hypertension, cardiovascular disease and diabetes mellitus.
2 Small lesion: !100 mm2 as maximal hypodense area on the cranial CT scan with the largest demarcation.
3 Moderate lesion: 100–500 mm2.
4 Large lesion with hypodense area: 1500 mm2.
Table 2. Antioxidant markers in patients with acute ischemic stroke in comparison to patients with a history of
stroke
Laboratory
reference
values
Patients with
a history of
stroke
(n = 17)
Patients with acute stroke (n = 11)
admission day 1 day 3 day 7
MDA i.S., Ìmol/l 1.6–2.4 1.7B0.5 2.1B0.6 1.9B0.4 1.9B0.3 1.7B0.2
GSHPx i.S., U/l 96–150 113B36 128B44 153B37b 165B55c 147B61
GSH i.B., Ìmol/l 68–97 58B23 84B26a 78B39 81B42 77B34
SOD i.B., U/Ìmol Hb 15–22 12.2B2.1 12.2B2.9 12.7B4.3 10.7B1.2 12.8B2.6
Se i.S., Ìmol/l 0.72–1.33 0.93B0.14 0.78B0.12a 0.78B0.14 0.77B0.16 0.82B0.13
Fe i.B., Ìmol/l 52–96 73B9 66B13 73B12 69B13 72B9
i.S. = In serum; i.B. = in whole blood/lysate.
a p ! 0.01 compared to patients at stroke risk, b p ! 0.05 compared to patients at stroke risk, c p = 0.07 compared to
patients at stroke risk. Laboratory reference values have been established before from 101 healthy subjects.
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Fig. 1. Negative correlation of the NIHSS score and serum GSHPx
levels on day 0 (r = –0.84, p ! 0.001) and day 7 (r = –0.63, p ! 0.05).
Discussion
We could identify some differences of antioxidant
markers and enzymes between patients with acute stroke
in comparison to age- and risk-matched patients with a
history of ischemic stroke: most significant differences
could be found for the GSH system, while MDA levels
showed only a trend for elevation in the first hours after
acute stroke.
The role of endogenous defense mechanisms including
antioxidant enzymes in stroke risk and arteriosclerosis is
controversial [3]. On the one hand, decreased availability
of antioxidant defense mechanisms is a chronic problem
in arteriosclerosis. On the other hand, the amount of oxi-
dative stress and acute changes of antioxidant capacity
might influence the prognosis of cerebral ischemia [2].
MDA levels are widely accepted as markers of lipid
peroxidation in states of increased oxidative stress. Some
but not all authors have found increased MDA levels after
acute stroke [12–14]. Our patients with acute stroke
showed a trend for MDA elevation during the first hours
after the event decreasing to levels similar to those of
stroke risk patients after 7 days.
GSH is part of the intracellular nonenzymatic small-
molecule antioxidant defense system. It is a free radical
scavenger and a proton donor for GSHPx and known to
play a neuroprotective role [15, 16]. Depleted GSH levels
have been found in a number of neurodegenerative dis-
eases with states of oxidative stress as well as in the pro-
cess of normal aging [15]. Nearly two thirds of our
patients with a stroke in the past showed decreased GSH
levels, possibly associated with increased oxidative stress
and arteriosclerosis. In animal models, acute increase in
GSH by activation of GSH synthase has been found dur-
ing acute oxidative stress [17]. Our patients had elevated
GSH levels during the first hours after acute stroke. This
could be part of a first-line defense mechanism against
oxidative stress, providing neuroprotection against amino
acid excitotoxicity in stroke [16].
Changes in enzymatic antioxidative defense mecha-
nisms after acute stroke are controversial. Some authors
found reduced SOD activity in red blood cells and serum
of patients with acute stroke [5, 13]. Reduced SOD levels
led to an enhancement and progression of cerebral infarc-
tions [5, 18]. Others have found increased levels of SOD
in red blood cells after cerebrovascular events [19]. We
did not find any significant differences of erythrocyte
SOD activity or its cofactors copper and zinc between the
two groups and there was no correlation between erythro-
cyte SOD activity and infarct size or NIHSS score in our
patients. Anyhow, the patient number might be too small
to draw negative conclusions and infarctions might not
have been large enough to have obvious influence on
whole blood SOD levels.
In our study, acute stroke was associated with in-
creased serum levels of GSHPx during the first and third
day after the acute event compared to patients with a his-
tory of stroke. Zachara et al. [20] found increased plasma
GSHPx levels up to 48 h after myocardial infarction and
Cherubini et al. [18] a significant increase in plasma
GSHPx activity between day 1 and 6 after acute stroke.
On the other hand, autopsied human brain tissue was
GSHPx positive only 6 days after acute stroke [21] and
red blood cell GSHPx activity even decreased in patients
with acute ischemic stroke [13]. Differences could be
explained by the fact that plasma GSHPx mainly origi-
nates from hepatocytes [22], while glial cells were found to
be the major source of brain GSHPx [21].
Several animal studies have found that GSHPx has
protective effects on brain damage and that reduced
GSHPx levels are associated with an increased stroke risk
[23, 24]. Data from our patients at stroke risk fit this con-
cept, showing that high GSHPx levels correlated with low
neurologic deficit (low NIHSS score on admission) as well
as good outcome (low NIHSS score on day 7).
Selenium was the only mineral found to be decreased
in acute stroke patients in our study. Acute decrease in
selenium levels in serum are associated with acute inflam-
matory processes [25]. Bor et al. [26] found decreased
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selenium levels after acute myocardial infarction. Levels
of our stroke risk patients were in the normal range, while
levels were decreased after acute stoke. We can only spec-
ulate that this is due to acute inflammatory processes after
stroke.
There are limitations of our study and the number of
examined patients is small. Only 4 of the 11 patients with
acute infarction developed severe stroke and large cere-
bral ischemic lesion; most of the patients only had minor
or no permanent deficit. This might explain why we could
only find small changes of the antioxidant system. How-
ever, we could show that there are differences of the
antioxidant status between patients at stroke risk and
patients with acute stroke. Our data support the hypothe-
sis that in acute stroke, activation of the GSH system
helps to overcome oxidative stress. It is possible that anti-
platelet drugs might have influenced the antioxidant sys-
tems as well. However, the use of stroke prevention drugs
was similar in both groups and all stroke patients were
treated with either ASS, clopidogrel or anticoagulation
after exclusion of intracerebral hemorrhage. Nevertheless,
further studies are needed to find out whether antioxidant
changes will have prognostic and therapeutic implications
for stroke and stroke risk patients.
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